Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem Cell Trial of Recovery EnhanceMent After Stroke (STEMS) Pilot Randomized, Controlled Trial (ISRCTN 16784092)

Sprigg, Nikola and Bath, Philip M.W. and Zhao, Lian and Willmot, Mark and Gray, Laura J. and Walker, Marion F. and Dennis, Martin S. and Russell, Nigel (2006) Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem Cell Trial of Recovery EnhanceMent After Stroke (STEMS) Pilot Randomized, Controlled Trial (ISRCTN 16784092). Stroke, 37 . pp. 2979-2983.

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (252kB)

Abstract

Background and Purpose - Loss of motor function is common after stroke and leads to significant chronic disability. Stem cells are capable of self-renewal and of differentiating into multiple cell types, including neurones, glia, and vascular cells. We assessed the safety of granulocyte-colony-stimulating factor (G-CSF) after stroke and its effect on circulating CD34 stem cells.

Methods - We performed a 2-center, dose-escalation, double-blind, randomized, placebo-controlled pilot trial (ISRCTN 16784092) of G-CSF (6 blocks of 1 to 10 g/kg SC, 1 or 5 daily doses) in 36 patients with recent ischemic stroke. Circulating CD34 stem cells were measured by flow cytometry; blood counts and measures of safety and functional outcome were also monitored. All measures were made blinded to treatment.

Results - Thirty-six patients, whose mean SD age was 768 years and of whom 50% were male, were recruited. G-CSF

(5 days of 10 g/kg) increased CD34 count in a dose-dependent manner, from 2.5 to 37.7 at day 5 (area under curve, P0.005). A dose-dependent rise in white cell count (P0.001) was also seen. There was no difference between

treatment groups in the number of patients with serious adverse events: G-CSF, 7/24 (29%) versus placebo 3/12 (25%),

or in their dependence (modified Rankin Scale, median 4, interquartile range, 3 to 5) at 90 days.

Conclusions - ”G-CSF is effective at mobilizing bone marrow CD34 stem cells in patients with recent ischemic stroke.

Administration is feasible and appears to be safe and well tolerated. The fate of mobilized cells and their effect on

functional outcome remain to be determined. (Stroke. 2006;37:2979-2983.)

Item Type: Article
Uncontrolled Keywords: ischemic stroke; stem cells; colony-stimulating factors; stroke recovery
Schools/Departments: University of Nottingham UK Campus > Faculty of Medicine and Health Sciences > School of Medicine > Division of Clinical Neuroscience
Related URLs:
URLURL Type
http://stroke.ahajournals.org/Publisher
Depositing User: Sayers, Hazel
Date Deposited: 16 May 2007
Last Modified: 29 Sep 2014 15:29
URI: http://eprints.nottingham.ac.uk/id/eprint/508

Actions (Archive Staff Only)

Edit View Edit View